Evaluation of an enzyme immunoassay for clinical diagnosis of neurocysticercosis in symptomatic patients

Carvalho, Reynaldo Mendes de; Costa, Dorcas Lamounier; Soares, Savyo Carvalho; Costa, Carlos Henrique Nery

doi:10.1590/s0037-86822010000600009

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The LLGP‐EITB, however, is technically complicated, requires sophisticated laboratory capacity and is not widely available. Despite previously published data pointing to inferior diagnostic performance , many investigators still use antibody detection by ELISA for diagnostic purposes . Commercial ELISA assays are offered by most diagnostic laboratories in the United States and Europe, and globally ELISA for antibody is the most commonly performed serologic assay for cysticercosis.…”

Section: Introductionmentioning

confidence: 99%

Low sensitivity and frequent cross‐reactions in commercially available antibody detection ELISA assays for Taenia solium cysticercosis

Garcı́a

Castillo²,

Gonzáles

et al. 2017

Tropical Med Int Health

View full text Add to dashboard Cite

Abstractobjective To evaluate the diagnostic performance of two commercially available ELISA kits, Novalisa â and Ridascreen â , for the detection of antibodies to Taenia solium, compared to serological diagnosis of neurocysticercosis (NCC) by LLGP-EITB (electro-immunotransfer blot assay using lentillectin purified glycoprotein antigens).methods Archive serum samples from patients with viable NCC (n = 45) or resolved, calcified NCC (n = 45), as well as sera from patients with other cestode parasites (hymenolepiasis, n = 45 and cystic hydatid disease, n = 45), were evaluated for cysticercosis antibody detection using two ELISA kits, Novalisa â and Ridascreen â . All NCC samples had previously tested positive, and all samples from heterologous infections were negative on LLGP-EITB for cysticercosis. Positive rates were calculated by kit and sample group and compared between the two kits.results Compared to LLGP-EITB, the sensitivity of both ELISA assays to detect specific antibodies in patients with viable NCC was low (44.4% and 22.2%), and for calcified NCC, it was only 6.7% and 4.5%. Sera from patients with cystic hydatid disease were highly cross-reactive in both ELISA assays (38/45, 84.4%; and 25/45, 55.6%). Sera from patients with hymenolepiasis cross-reacted in five cases in one of the assays (11.1%) and in only one sample with the second assay (2.2%).conclusions The performance of Novalisa â and Ridascreen â was poor. Antibody ELISA detection cannot be recommended for the diagnosis of neurocysticercosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Low sensitivity and frequent cross‐reactions in commercially available antibody detection ELISA assays for Taenia solium cysticercosis

Garcı́a

Castillo²,

Gonzáles

et al. 2017

Tropical Med Int Health

View full text Add to dashboard Cite

show abstract

Screening for neurocysticercosis in internationally adopted children: yield, cost and performance of serological tests, Italy, 2001 to 2016

et al. 2018

View full text Add to dashboard Cite

IntroductionNeurocysticercosis (NCC) is one of the leading causes of epilepsy worldwide. The majority of cases in Europe are diagnosed in immigrants. Currently in Italy, routine serological screening for cysticercosis is recommended for internationally adopted children (IAC) coming from endemic countries. Methods: We retrospectively analyse the results of the serological screening for cysticercosis in IAC 16 years old or younger, attending two Italian third level paediatric clinics in 2001–16. Results: Of 2,973 children included in the study, 2,437 (82.0%) were screened by enzyme-linked immune electro transfer blot (EITB), 1,534 (51.6%) by ELISA, and 998 (33.6%) by both tests. The seroprevalence of cysticercosis ranged between 1.7% and 8.9% according to EITB and ELISA, respectively. Overall, 13 children were diagnosed with NCC accounting for a NCC frequency of 0.4% (95% confidence interval (CI): 0.2–0.6%). Among the 168 seropositive children, only seven (4.2%) were diagnosed with NCC. Of these children, three were asymptomatic and four presented epilepsy. Among seronegative children (n = 2,805), seven presented with neurological symptoms that lead to the diagnosis of NCC in six cases. The sensitivity, specificity, positive and negative predictive value for the diagnosis of NCC were 54.5%, 98.6%, 14.6%, 99.8% for EITB and 22.2%, 91.1%, 1.4%, 99.5% for ELISA. The yield of the screening programme was 437 NCC cases per 100,000. The number needed to screen to detect one NCC case was 228. The cost per NCC case detected was EUR 10,372. Conclusion: On the base of our findings we suggest the ongoing serological screening for cysticercosis to be discontinued, at least in Italy, until further evidence in support will be available.

show abstract

From laboratory to clinical practice: an update of the immunological and molecular tools for neurocysticercosis diagnosis

Toribio,

Bustos,

Garcia

2024

Front. Parasitol.

View full text Add to dashboard Cite

Neurocysticercosis (NCC) is caused by the invasion of Taenia solium larvae in the central nervous system (CNS) and stands as the predominant cause of epilepsy and other neurological disorders in many developing nations. NCC diagnosis is challenging because it relies on brain imaging exams (CT or MRI), which are poorly available in endemic rural or resource-limited areas. Moreover, some NCC cases cannot be easily detected by imaging, leading to inconclusive results. Multiple laboratory assays, principally immunological, have been developed to support the diagnosis and/or monitor the treatment efficacy, but its production can be costly, laborious, and non-globally accessible because they depend on parasite material. Therefore, recent advances have been focused on the implementation of recombinant or synthetic antigens as well as monoclonal antibodies for NCC immunodiagnosis purposes. Similarly, molecular diagnosis has been explored, obtaining promising results. Here we described the recent progress in the development of immunological and molecular diagnostic tools for NCC diagnosis over the past 13 years, discussing their potential application to address important challenges and how to focus future directions to improve NCC diagnosis with emphasis on enhance accessibility and the importance of test validation to provide an adequate support for clinical decisions.

show abstract

Evaluation of an enzyme immunoassay for clinical diagnosis of neurocysticercosis in symptomatic patients

Cited by 3 publications

References 21 publications

Low sensitivity and frequent cross‐reactions in commercially available antibody detection ELISA assays for Taenia solium cysticercosis

Low sensitivity and frequent cross‐reactions in commercially available antibody detection ELISA assays for Taenia solium cysticercosis

Screening for neurocysticercosis in internationally adopted children: yield, cost and performance of serological tests, Italy, 2001 to 2016

From laboratory to clinical practice: an update of the immunological and molecular tools for neurocysticercosis diagnosis

Contact Info

Product

Resources

About